Howard University Hospital

Efficacy of rituximab plus lenalidomide regimens in follicular lymphoma: a meta-analysis of randomized controlled trials

Follicular lymphoma (FL) is an incurable, indolent non-Hodgkin lymphoma with a high relapse rate despite effective chemoimmunotherapy. Lenalidomide, an immunomodulatory agent, in combination with rituximab (R²), has been evaluated as an alternative to chemoimmunotherapy and to ot...